Abstract
Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a high-affinity Synaptic Vesicle protein2A (SV2A) ligand that exceeds the binding potential of Levetiracetam (LEV). In the European Union, BRV is only approved as an adjunctive therapy for the treatment of Partial-Onset Seizures (POS) with or without secondary generalization, in patients 4 years of age and older with epilepsy, while F.D.A. has recently approved its use as monotherapy in partial-onset seizures in adults. In Phase III clinical trials, BRV has shown efficacy and an adequate safety profile in patients suffering from POS. In additional open-label studies, BRV has demonstrated satisfying results and high retention rates in patients with both focal – onset and genetic generalized epilepsies. The main Treatment-Emergent Adverse Events (TEAEs) observed during the regulatory and open label trials were somnolence, dizziness and headache following by fatigue and nausea. Brivaracetam seems to be an effective, easy to use and safe antiepileptic drug in clinical setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
